Search research articles
Contact Us
Filters
Showing results (71-80 of 152) with videos related to
Page
of 16
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 21, 2019
An <sup>18</sup>F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with <sup>18</sup>F-JK-PSMA-7 During the First Year of Application
Felix Dietlein, Melanie Hohberg, Carsten Kobe, et al.
EJNMMI Research
|
January 10, 2025
Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy
Jan Heilinger, Katrin Sabine Roth, Henning Weis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 12, 2009
Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial
Christian Furth, Ingo G Steffen, Holger Amthauer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 3, 2016
PSA-Stratified Performance of <sup>18</sup>F- and <sup>68</sup>Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer
Felix Dietlein, Carsten Kobe, Stephan Neubauer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 9, 2018
Metabolic Tumour Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma
Jasmin Mettler, Horst Müller, Conrad-Amadeus Voltin, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
April 25, 2012
Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib
Carsten Kobe, Matthias Scheffler, Arne Holstein, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 9, 2011
Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET
Deniz Kahraman, Matthias Scheffler, Thomas Zander, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 20, 2019
Intraindividual Comparison of <sup>18</sup>F-PSMA-1007 with Renally Excreted PSMA Ligands for PSMA PET Imaging in Patients with Relapsed Prostate Cancer
Felix Dietlein, Carsten Kobe, Melanie Hohberg, et al.
Hemasphere
|
August 11, 2025
Working towards harmonization of clinical trial reporting in Hodgkin lymphoma
Carsten Kobe, Philippe Armand, Sven Borchmann, et al.
Clinical Nuclear Medicine
|
January 14, 2021
Lymph Node Assessment in Prostate Cancer: Evaluation of Iodine Quantification With Spectral Detector CT in Correlation to PSMA PET/CT
Simon Lennartz, Philipp Täger, David Zopfs, et al.
Page
of 16
Search research articles
Search
Showing results (71-80 of 152) with videos related to
Sort By:
Page
of 16
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 21, 2019
An <sup>18</sup>F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with <sup>18</sup>F-JK-PSMA-7 During the First Year of Application
Felix Dietlein, Melanie Hohberg, Carsten Kobe, et al.
EJNMMI Research
|
January 10, 2025
Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy
Jan Heilinger, Katrin Sabine Roth, Henning Weis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 12, 2009
Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial
Christian Furth, Ingo G Steffen, Holger Amthauer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 3, 2016
PSA-Stratified Performance of <sup>18</sup>F- and <sup>68</sup>Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer
Felix Dietlein, Carsten Kobe, Stephan Neubauer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 9, 2018
Metabolic Tumour Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma
Jasmin Mettler, Horst Müller, Conrad-Amadeus Voltin, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
April 25, 2012
Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib
Carsten Kobe, Matthias Scheffler, Arne Holstein, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 9, 2011
Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET
Deniz Kahraman, Matthias Scheffler, Thomas Zander, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 20, 2019
Intraindividual Comparison of <sup>18</sup>F-PSMA-1007 with Renally Excreted PSMA Ligands for PSMA PET Imaging in Patients with Relapsed Prostate Cancer
Felix Dietlein, Carsten Kobe, Melanie Hohberg, et al.
Hemasphere
|
August 11, 2025
Working towards harmonization of clinical trial reporting in Hodgkin lymphoma
Carsten Kobe, Philippe Armand, Sven Borchmann, et al.
Clinical Nuclear Medicine
|
January 14, 2021
Lymph Node Assessment in Prostate Cancer: Evaluation of Iodine Quantification With Spectral Detector CT in Correlation to PSMA PET/CT
Simon Lennartz, Philipp Täger, David Zopfs, et al.
Page
of 16